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A series of novel dimethyl 7-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-
yl)-4-(4-fluorophenyl)-9-oxo-8-phenyl-6-thia-1,2,8-triazaspiro[4.4]non-2-en-3-ylphosphonate 11a-g have been synthesized 
by the reaction of chalcone derivatives of (E)-5-benzylidene-2-((2S,3S)-3-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-
yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-3-phenylthiazolidin-4-one 10a-g with Bestmen Ohira reagent. The chemical 
structures of newly synthesized compounds have been elucidated by IR, NMR, MS and elemental analysis. The compounds 
11a-g have been evaluated for their nematicidal activity against Dietylenchus myceliophagus and Caenorhabditis elegans. 
Compound 11b, 11c, 11g and 11f show appreciable nematicidal activity. 
Keywords:  Phosponylpyrazoles, Bestmenohira reagent, click reaction, Knovenagel condensation, cyclisation, nematicidal 
activity 
1,2,3-Triazoles are one of the most important classes 
of heterocyclic organic compounds, which are 
reported to present in a plethora of biological 
activities for diverse therapeutic areas1. The 1,2,3-
triazole motif is associated with diverse 
pharmacological activities such as antibacterial, 
antifungal, hypoglycemic, antihypertensive and 
analgesic properties2. Polysubstituted five-membered 
aza heterocyclic’s rank the most potent glycosidase 
inhibitors3. Further, this nucleus in combination with 
or in linking with various other classes of compounds 
such as amino acids, steroids, aromatic compounds, 
carbohydrates, etc. became prominent in having 
various pharmacological properties4. 1,2,3-Triazole 
modified carbohydrates have became easily available 
after the discovery of the Cu(I) catalyzed azide-
alkynes 1,3-dipolar cycloaddition reaction5 and 
quickly became a prominent class of non-natural 
sugars. The chemistry and biology of triazole 
modified sugars is dominated by Triazole glycosides6. 
Therefore, the synthesis and investigation of 
biological activity of 1,2,3-triazole glycosides is an 
important objective, which also received the 
considerable attention by the medicinal chemists. 
Thiazoles are familiar group of heterocyclic 
compounds possessing a wide variety of biological 
activities and their utility as medicine is very much 
established7. Thiazole nucleus is also an integral part 
of all the available penicillins which have 
revolutionized the therapy of bacterial diseases8. 
Chemistry of thiazolidenone ring system is one 
considerable interest as it core structure in various 
synthetic pharmaceuticals displaying a broad 
spectrum biological activities9. The thiazolidenone 
nucleus also appears frequently in the structure of 
various natural products notably thiamine, compounds 
possessing cardiac and glycemic benefits such as 
troglitazone10 and many metabolic products of fungi 
and primitive marine animals, including 2-
(aminoalyl)–thiazole–4-carboxylicacids11. Numerous 
thiazolidenone derivatives have shown significant bio 
activities such as antidiarrhoeal12, anticonvulsant13, 
antimicrobial14, antidiabetic15, antihistaminic16, 
anticancer17, anti HIV18, Ca+2 channel blocker19, PAF 
antagonist20, cardioprotective21, antiischemic22, COX 
inhibitory23, antiplatelet activating factor24, non- 
peptide thrombin receptor antagonist25, tumor necrosis 
factor- α antagonist26 and nematicidal activities. 
Organo phosphorus compounds continue to attract 
much attention because of their various potent 
biological activities27 in particular, phosphonates are 
important synthetic derivatives which can have often 
act as phosphate and carboxylic acid mimics, and 
interfere with enzymatic processes. Much of this 




activity has been attributed to the relatively inert 
nature of the C-P bond27, which is not easily 
hydrolyzed as compared to the P-O bond found in 
phosphates. The synthesis and biological activities of 
important natural and non natural phosphonate 
derivatives, including Phosponated aza heterocyclics 
and nucleotides has been reviewed28. In view of the 
importance of heterocyclics bearing a phosphonate 
group, new synthetic methods that would allow 
straightforward access to these versatile building 
blocks are needed27,29. Among the various bioactive 
heterocyclics the pyrazole moiety remains of great 
interest because of its wide applications in the 
pharmaceutical and agrochemical industry30,31. In 
addition, pyrazoles also play a central role in 
coordination chemistry32. 
Nematodes are tiny worms, some of them are plant 
parasites, and can play an important role in the 
predisposition of the host plant to the invasion by 
secondary pathogens33. Plants attacked by nematodes 
show retarded growth and development, as well as 
loss in the quality and quantity of the harvest. The 
nematicide use is slated for reduction due to 
environmental problems, and human and animals 
health concern. For example, effective nematicides 
such as dibromochloropropane (DBCD) and ethylene 
dibromide (EDB) have been withdrawn from the 
market due to their deleterious effects on human and 
the environment. Methyl bromide, the most effective 
and widely used fumigant for soil borne pests 
including nematodes, has already been banned. 
The use of nonfumigant nematicides, based on 
organophosphates and carbamates, is expected to 
increase the withdrawal of methyl bromide, which will 
bring about new environmental concerns. In fact, the 
highly toxic Aldicarb used to control insects and 
nematodes has been detected in ground water34. 
Therefore alternative nematode control methods or less 
toxic nematicides need to be developed35.One way of 
searching for such nematicidal compounds is to screen 
naturally occurring compounds in plants. Several such 
compounds, e.g. alkaloids, phenols, sesquiterpenes, 
diterpenes, polyacetylenes, and thienyl derivatives have 
nematicidal activity36. For example, -terthienyl is a 
highly effective nematicidal compound37. Other 
compounds with nematicidal activity have been isolated 
from plants, mainly from the family Asteraceae36. 
However, compounds of plant origin and their analogs 
have not been developed into commercial nematicides; 
hence there is a need to develop commercial synthesis. 
Following the successful introduction of 
nematicidal agents, inspired by the biological profile 
of triazoles, thiazoles, Phosponylpyrazoles. In 
continuation of our work on biological active 
molecules38-46 it was thought to interest to accomidate 
all those moieties in single molecular frame work. In 
this article we wish to report the synthesis of a new 
class of hybrid heterocyclic’s 11a-g in good yields 
and their evaluated nematicidal activity. 
 
Result and Discussion 
The key intermediate, 8 required for the 
synthesis of title compound was prepared according 
to the procedure outlined in the Scheme I. Di acetyl 
D-Glucal (2) prepared from 3,4,6-tri- O-acetyl  
D-Glucal by treating with triethyl silane and Boron 
Tri fluoride diethyl etherate, de acylation of 2, with 
NaOMe in Methanol at 0°C for 1h gave 3 (77%), 
which on subsequent treatment with TBDMSCl in 
Dichloromethane in presence of NEt3 for 12h 
afforded TBS ether 4 (80%),on treatment with 
propargyl bromide in toluene in presence of tetra 
butyl ammonium hydrogen sulphate produced di 
ether 5.After deprotection of TBS ether the 
propargyl ether converted into Triazole 7 (82%) by 
using 1,3-Dipolar cycloaddition with p-chloro 
phenyl azide was carried out at ambient 
temperature in the presence of CuSO4 and sodium 
ascorbate in a mixture of 1:1 CH2Cl2–H2O. 
Oxidation of 7 with IBX in acetonitrile afforded 
compound 8. Subsequently one pot synthesis of 
Triazole linked Thiazolidenone glycosides was 
carried out by the condensation reaction between 8, 
primary aromatic amine and a thio glycolic acid in 
presence of ZnCl2 under microwave irradiation 
(Scheme I).The reaction is completed in only  
5-10 minutes and the compounds, isolated by 
conventional work-up, 9a-g are obtained in 
satisfactory yields, Compound 9a-g was then 
reacted with p-fluorobenzaldehyde in presence  
of anhydrous NaOAc in glacial AcOH at  
reflux temperature gave chalcone derivatives of 
Triazole linked Thiazolidenone glycosides  
10a-g, on cyclocondensation under conventional 
and microwave irradiation with Bestmen  
Ohira reagent in presence of anhydrous KOH  
gave Compounds 11(a-g). The structures of 
synthesized compounds were confirmed by IR, 
NMR, MS and elemental analysis. Further  
the compounds were subject to nematicidal  
activity testing. 




Nematicidal activity  
The compounds synthesized 10a-g in this study were 
also screened for their nematicidal activity against 
Dietylenchus myceliophagus and Caenorhabditis 
elegans by aqueous in vitro screening technique46 at 
various concentrations. The nematicidal activity of each 
test compound was compared with the standard drug 
Levamisole. The results have been expressed in terms of 
LD50 i.e. median lethal dose at which 50% nematodes 
became immobile (dead). The screened data reveal that, 
compounds 11b, 11c, 11f and 11g are the most effective 
against Dietylenchus myceliophagus and Caenorhabditis 
elegans the other test compounds showed moderate 
activity. The LD 50 values of the test compounds 
screened are presented in Table I. 
 
Experimental Section 
Commercial grade reagents were used as supplied. 
Solvents except analytical reagent grade were dried 
and purified according to literature when necessary. 
Di-methyl 2-oxopropyl phosphonate was purchased 
from Aldrich for the synthesis of Bestmen Ohira 
reagent. Reaction progress and homogeneity of the 
compounds were checked by thin-layer 
chromatography (TLC) on pre-coated silica gel F254 
plates from Merck and compounds visualized either 
by exposure to UV light or dipping in 1% aqueous 




Table I — Nematicidal activity of 11a-g 
Compd LD50 Value (ppm) 
D. myceliophagus C. elegans 
11a 740 860 
11b 220 280 
11c 320 270 
11d 501 540 
11e 960 900 
11f 209 210 
11g 310 360 
Levamisole 160 180 




chromatographic columns (60–120 mesh) were used 
for separations. Optical rotations were measured on 
an Perkin-Elmer 141 polarimeter by using a 2 mL cell 
with a path length of 1 dm with CHCl3 or CDCl3 as 
solvent. All melting points are uncorrected and 
measured using Fisher-Johns apparatus. IR spectra 
were recorded as KBr disks on a Perkin-Elmer FT-IR 
spectrometer. Microwave reactions are carried out in 
mini lab microwave catalytic reactor (ZZKD, WBFY-
201). The 1H NMR and 13C NMR spectra were 
recorded on a Varian Gemini spectrometer (300 MHz 
for 1H and 75 MHz for13C). Chemical shifts are 
reported as δ (ppm) against TMS as internal reference 
and coupling constants (J) are reported in Hz units. 
Mass spectra were recorded on a VG micro mass 
7070H spectrometer. Elemental analysis (CHN) 
determined by a Perkin-Elmer 240 CHN elemental 
analyzer, were within ± 0.4% of theoretical. 
 
((2R,3S)-3-Acetoxy-3,6-dihydro-2H-pyran-2-
yl)methyl acetate, 2 
Tri-O-acetyl-D-glucal (1) (3.0 g, 11. 02 mmol) was 
dissolved in anhydrous dichloromethane(5 mL).The 
solution was cooled to 0°C, tri ethyl silane (1.53 
g,13.22 mmol) was added and the mixture was stirred 
for 5 min. Thereafter, boron trifluoride diethyl 
etherate (690 μL of a40 w% solution in diethyl ether, 
11.02 mmol) was added drop-wise and the reaction 
mixture was stirred for 90 min. The mixture was 
poured into a saturated solution of NaHCO3. The 
organic layer was washed with water, dried over 
Na2SO4 and concentrated under reduced pressure. 
Column chromatography on silica gel (PE/EtOAc, 
3:1) yielded the title compound (2.24 g, 10.42 mmol, 
95%) as a colourless syrup. [α]D20: +115.5° (c = 1.00, 
CHCl3). 
1H NMR (300 MHz, CDCl3 ): δ 5.87-5.84 
(m, 2H, =CH), 4.95 (t, 1H, OCH), 4.03-3.99 (m, 1H, 
CH), 4.12- 4.09 (m, 4H, OCH2), 2.20 (s, 6H, CO C 
H3); 
13C NMR (75 MHz, CDCl3):  170.2, 127.2, 
125.8, 73.6, 65.1, 64.0, 62.5, 21.1; MS: m/z (M++H) 
215. Anal. Calcd for C10H14O5: C, 56.07; H, 6.59. 




Diacetate 2 (17.22 mmol) was treated by a catalytic 
amount of sodium methoxide in methanol (100 mL) at 
RT. After evaporation of the solvent,the free hydroxyl 
unsaturated glycoside was obtained in quantitative 
yield and used without further purification. This diol 
was treated with 2.50 equiv of TBD MSCl (3.14 g, 
21.14 mmol), 2.6 equiv of NEt3 (3.2 mL,22.4 mmol), 
and 0.05 equiv of imidazole (30 mg, 0.43 mmol) in 
CH2Cl2 (30 mL) at RT for ca. 24 h (until TLC 
analysis showed no more starting material). After 
addition of 25 mL of water and extraction with 
3×30 mL of CH2Cl2, the organic layer was dried. 
After evaporation of the solvent under reduced 
pressure, the residue was purified by column 
chromatography using petroleum ether/ethyl acetate 
as the eluent yielded the title compound (1.94 g, 10.42 
mmol, 85%) as a colourless syrup. 1H NMR (300 
MHz, CDCl3 ): δ 6.0-5.82 (m, 2H, =CH), 5.42 (d, 
J=6.5Hz, 1H, CH), 4.50 (brs, 1H, OH), 4.20-4.12 (m, 
1H, CH), 3.91-3.80 (m, 4H, CH2), 0.98 (s, 9H, t-Bu), 
0.24 (s, 6H, CH3); 
13C NMR (75 MHz, CDCl3):  
127.5, 125.6, 84.6, 81.5, 73.6, 62.7, 25.6, 18.1; MS: 
m/z (M++Na) 267. Anal. Calcd for C12H24O3Si: C, 




To a solution of alcohol 4 (400 mg, 1.63 mmol, 1.0 
equiv) in toluene (1.6 mL) was added a 35% aqueous 
solution of NaOH (1.6 mL), propargyl bromide (80% 
solution in toluene, 363 μL, 2.4 mmol, 1.5equiv), and 
n-Bu4NHSO4 (280 mg, 0.82 mmol, 0.5 equiv). After 6 
h of vigorous stirring at RT, Et2NH (1.6 mL) was 
added. The reaction mixture was stirred for 1 h, 
poured into ice water, cautiously neutralized by 
addition of a 3M solution of hydrochloric acid, and 
extracted with EtOAc. The combined organic extracts 
were washed with brine, dried over MgSO4, filtered, 
and concentrated under reduced pressure. The crude 
material was purified by flash chromatography on 
silica gel (hexane/EtOAc 85:15) to afford propargyl 
ether as colorless oil (0.345g, 75%). 1H NMR  
(300 MHz, CDCl3): δ 6.03-5.80 (m, 2H, =CH), 4.69  
(t, J= 3.9Hz 1H, CH), 3.68 (dd, J= 8.9Hz, 4.1Hz, 1H, 
OCH), 3.99-3.89 (m, 6H, CH2), 3.20 (s, 1H, CH), 0.96 
(s, 9H, t-Bu), 0.23 (s, 6H, CH3); 
13C NMR (75 MHz, 
CDCl3):  127.2, 124.9, 78.0, 76.2, 74.2, 64.2, 63.2, 
58.5, 25.3, 18.5; MS: m/z (M++H) 283. Anal. Calcd 





To a stirred solution of 5 (0.325g) in tetrahydro- 
furan catalytic amount of TBAF was added and 
stirred the reaction mixture at RT for 15 min, 
extracted the product with ethyl acetate (20 mL). The 




combined organic extracts were washed with brine, 
dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude material was purified by 
flash chromatography on silica gel (60-120 mesh, 
hexane/EtOAc 70:30) to afford alcohol as yellow oil 
(0.285 g, 85%). 1H NMR (300 MHz, CDCl3): δ 5.95-
5.75 (m, 2H, =CH), 4.65 (d, J=3.9Hz, 1H,CH), 4.52 
(brs, 1H, OH), 4.09-4.11 (m, 4H, OCH2), 3.64 (dd, J= 
4.1Hz, 8.9Hz, 1H, OCH), 3.76 (d, J=6.8Hz, 2H, 
OCH2), 3.28 (s, 1H, CH): 
13C NMR (75 MHz, 
CDCl3):  127.2, 125.6, 78.3, 76.1, 74.1, 64.2, 61.4, 
58.0; MS: m/z (M++H) 169. Anal. Calcd for C9H12O3: 




To a solution containing alkyne 6 (0.250 g, 0.778 
mmol), p-chlorophenyl azide (0.130 g, 0.849 mmol) 
in dichloromethane (10 mL ) and water (10 mL ) were 
added CuSO4.5H2O (0.110 g) and sodium ascorbate 
(0.114 g). The resulting suspension was stirred at RT 
for 6h. After this time, the mixture was diluted with 
5 mL dichloromethane and 5 mL water. The organic 
phase was separated, dried with sodium sulphate and 
concentrated at reduced pressure the crude product 
was purified by column chromatography on silica gel 
(60-120 mesh, hexane/EtOAc 65:35) to afford 7 
(0.290 g, 75%) as a white powder. m.p.149-151°C. 
1H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H, Ar-H), 
7.56 (d, J=9.2Hz, 2H, Ar-H), 7.45 (d, J=8.9Hz, 2H, 
Ar-H), 5.85-5.79 (m, 2H, =CH), 4.59 (s, 2H, OCH2), 
4.50 (brs, 1H, OH), 3.88-3.99 (m, 4H, OCH2), 3.8-
3.75 (m, 2H, OCH); 13C NMR (75MHz, CDCl3):  
140.9, 134.5, 134.1, 128.4, 127.5, 125.4, 122.1, 11.5, 
78.6, 68.5, 65.7, 64.2, 62.4; MS: m/z (M++H) 322. 
Anal. Calcd for C15H16ClN3O3: C, 55.90; H, 5.01, N, 





To a solution of alcohol 7 (0.120 g, 0.465 mmol) in 
CH2Cl2 (5 mL), catalytic amount of IBX was added at 
0°C and stirred at RT for 30 min. The reaction 
mixture was filtered and washed with CH2Cl2 
(2×10 mL). It was dried (Na2SO4) and evaporated to 
give aldehyde 7 (0.110 g) in quantitative yield as a 
yellow liquid, which was used as such for the next 
reaction. 
To a stirred mixture of 8 (0.110g, 0.373 mmol), 
aromatic amine (0.373 mmol) and anhydrous 
thioglycolic acid (0.140 g, 0.211 mmol) in dry toluene 
(5 mL), ZnCl2 ( 0.100 g, 0.751 mmol) was added after 
2 min and irradiated in microwave bath reactor at 280 
W for 4-7 min at 110°C. After cooling, the filtrate 
was concentrated to dryness under reduced pressure 
and the residue was taken up in ethyl acetate. The 
ethyl acetate layer was washed with 5% sodium 
bicarbonate solution and finally with brine. The 
organic layer was dried over Na2SO4 and evaporated 
to dryness at reduced pressure. The crude product thus 
obtained was purified by column chromatography on 





3-phenylthiazolidin-4-one, 9a: m.p. 157-159°C. 
Yield 75%. 1H NMR (300 MHz, CDCl3): δ 8.04(s, 
1H, Ar-H), 7.50 (d, J=9.2HZ, 2H, Ar-H), 7.40(d, 
J=8.9 HZ, 2H, Ar-H), 7.10-6.20 (m, 5H, Ar-H), 5.80-
5.71 (m, 2H, =CH), 4.90 (d, J=5.2 Hz, 1H, CH-S), 
4.52 (s, 2H, OCH2), 4.09-3.94 (m, 2×CH), 3.79 (d, 
J=6.6 Hz, 2H, OCH2), 3.72 (s, 2H, CH2 ); 
13C NMR 
(75 MHz, CDCl3):  170.4, 144.1, 141.8, 134.1, 
128.2, 125.6, 122.4, 119.4, 85.6, 72.6, 66.4, 64.0, 
51.4, 33.9; MS: m/z (M++H) 469. Anal. Calcd for 
C23H21ClN4O3S: C, 58.91; H, 4.51; N, 11.95. Found: 




dihydro-2H-pyran-2-yl)thiazolidin-4-one, 9b: m.p. 
226-228°C. Yield 69%. 1H NMR (300 MHz, CDCl3): 
δ 8.05 (s, 1H, Ar-H), 7.54 (d, J=9.4HZ, 4H, Ar-H), 
7.42(d, J=8.6HZ, 4H, Ar-H), 5.84-5.75 (m, 2H, =CH), 
4.94 (d, J=5.2 Hz, CH-S), 4.50 (s, 2H, OCH2), 4.06-
3.96 (m, 2H, 2×CH), 3.80 (t, 2H, OCH2), 3.72 (s, 2H, 
CH2): δ 
13C NMR (75 MHz, CDCl3):  170.5, 144.2, 
139.2, 134.2, 129.2, 125.5, 122.2, 119.4, 85.4, 72.8, 
65.4, 63.4, 51.2, 34.1; MS: m/z (M++Na) 525. Anal. 
Calcd for C23H20Cl2N4O3S: C, 54.88; H, 4.00, N, 





213°C. Yield 71%. 1H NMR (300 MHz, CDCl3): δ 
8.26 (d, J=8.7Hz, 2H, Ar-H), 8.03 (s, 1H, Ar-H), 7.61 
(d, J=9.4HZ, 2H, Ar-H), 7.46 (d, J=8.5HZ, 2H, Ar-H), 
6.84 (d, J=9.8Hz, 2H, Ar-H), 5.86-5.79 (m, 2H, 
=CH), 4.96 (d, J=5.2Hz, CH-S), 4.55 (s, 2H, OCH2), 




4.05-3.95 (m, 2H, 2×CH), 3.85 (d, J=6.9Hz, 2H, 
OCH2), 3.82 (s, 2H, CH2); 
13C NMR (75 MHz, 
CDCl3):  171.5, 144.0, 141.8, 134.2, 128.5, 125.4, 
119.5, 85.4, 72.4, 65.9, 63.6, 51.5, 34.6; MS: m/z 
(M++H) 514. Anal. Calcd for C23H20ClN5O5S: C, 





3-o-tolylthiazolidin-4-one, 9d: m.p.191-193°C. Yield 
65%. 1H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H, Ar-
H), 7.56 (d, J=9.2 Hz, 2H, Ar-H), 7.49 (d, J=8.7 Hz, 
2H, Ar-H), 7.45-7.39 (m, 4H, Ar-H), 5.76 (m, 2H, 
=CH), 4.93 (d, J=5.2 Hz, 1H, CHS), 4.60 (s, 2H, 
OCH2), 4.05-3.96 (m, 2H, CH), 3.90 (t, 2H, OCH2), 
3.81 (s, 2H, CH2), 2.1 (s, 3H, CH3); 
13C NMR (75 
MHz, CDCl3):  170.5, 144.2, 138.2, 134.2, 130.7, 
128.6, 125.6, 122.0, 119.5, 116.5, 85.4, 72.6, 65.8, 
63.4, 52.0, 32.3, 17.5; MS: m/z (M++H) 483. Anal. 
Calcd for C24H23ClN4O3S: C, 59.68; H, 4.80, N, 
11.60. Found: C, 59.48; H, 4.55; N, 11.49%. 
(R)-2-((2S,3S)-3-((1-(4-Chlorophenyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3,6-dihydro-2H-pyran-2-yl)-
3-p-tolylthiazolidin-4-one, 9e: m.p.195-198°C. Yield 
79%. 1H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H, Ar-
H), 7.51 (d, J= 9.2 Hz, 2H, Ar-H), 7.45 (d, J=8.7Hz, 
2H, Ar-H), 7.25 (d, J=8.2Hz, 2H, Ar-H), 6.84 (d, J= 
9.4 Hz, 2H, Ar-H), 5.72-5.68 (m, 2H, =CH), 4.95 (s, 
1H, CHS), 4.59 (s, 2H, OCH2), 4.04-3.99 (m, 2H, 
CH), 3.98 (t, 2H, OCH2), 3.90 (s, 2H, CH2), 2.32 (s, 
3H, CH3): 
13C NMR (75 MHz, CDCl3):  170.5, 
144.2, 138.6, 136.2, 14.1, 133.2, 129.4, 127.5, 122.5, 
119.5, 85.4, 72.0, 66.4, 63.5, 51.5, 34.0, 21.4; MS: 
m/z (M++H) 483. Anal. Calcd for C24H23ClN4O3S: C, 





3-(3-hydroxyphenyl)thiazolidin-4-one, 9f: m.p. 218-
219°C. Yield: 85%. 1H NMR (300 MHz, CDCl3): δ 
9.40 (brs, 1H, Ph-OH), 8.08 (s, 1H, Ar-H), 7.58 (d, 
J=9.3 Hz, 2H, Ar-H), 7.49 (d, J=8.6 Hz, 2H, Ar-H), 
6.83-6.76 (m, 4H, Ar-H), 5.72-5.68 (m, 2H,= CH), 
4.94 (d, J=5.2Hz, 1H, CHS), 4.64 (s, 2H, OCH2), 4.12 
(t, 2H, OCH2), 4.01-3.94 (m, 2H, CH), 3.92 (s, 2H, 
CH2); 
13C NMR (75 MHz, CDCl3):  170.5, 158.2, 
143.8, 134.5, 130.4, 128.6, 125.6, 122.4, 119.5, 114.8, 
106.5, 85.4, 72.5, 66.4, 63.4, 51.5, 34.1; MS: m/z 
(M++Na) 507. Anal. Calcd for C23H21ClN4O4S: C, 






275°C, Yield 82%. 1H NMR (300 MHz, CDCl3): δ 
9.42 (brs, 1H, Ph-OH), 8.05 (s, 1H, Ar-H), 7.56 (d, 
J=9.2 Hz, 2H, Ar-H), 7.46 (d, J=8.4 Hz, 2H, Ar-H), 
7.32 (d, J=8.6 Hz, 2H, Ar-H), 7.02 (d, J=8.8Hz, 2H, 
Ar-H), 5.89-5.80 (m, 2H,=CH), 4.96 (d, J=5.4 Hz, 
1H, CHS), 4.66 (s, 2H, OCH2), 4.09 (d, J=2H, OCH2), 
4.04-3.98 (m, 2H, CH), 3.94 (s, 2H, CH2); 
13C NMR 
(75 MHz, CDCl3):  170.9, 154.1, 144.4, 134.9, 
134.8, 128.8, 127.2, 125.6, 123.2, 119.4, 116.4, 85.4, 
72.6, 66.5, 64.0, 51.6, 34.5; MS: m/z (M++H) 485. 
Anal. Calcd for C23H21ClN4O4S: C, 59.96; H, 4.36, N, 
11.55. Found: C, 59.38, H, 4.75. N, 11.33%. 
 
General procedure for the synthesis of 10a-g 
A mixture of compound 9a (0.01 mol), p-
fluorobenzaldehyde (0.02 mol) and sodium acetate 
(0.01 mol) in anhydrous glacial acetic acid (20 mL ), 
was refluxed for 3 h. The reaction mixture was 
concentrated and then poured into ice cold water, the 
solid thus separated, was filtered, washed with water 
and crystallized from glacial acetic acid. To afford 





4-one, 10a: m.p. 235-237°C. Yield 85%. 1H NMR 
(300 MHz, CDCl3): δ 8.07 (s, 1H, Ar-H), 7.80 ( s, 1H, 
CH =C), 7.72 (d, J=9.6Hz, 2H, Ar-H), 7.40 (d, 
J=9.2HZ, 2H, Ar-H), 7.45 (d, J=8.9HZ, 2H, Ar-H), 
7.19 (d, J= 8.2 Hz, 2H, Ar-H), 7.02-6.80 (m, 5H, Ar-
H), 5.80-5.74 (m, 2H, =CH), 4.90 (d, J=5.2 Hz, 1H, 
CH-S), 4.52 (s, 2H, OCH2), 4.09-3.94 (m, 2H, 2×CH), 
3.79 (d, J=6.6 Hz, 2H, OCH2); 
13C NMR (75 MHz, 
CDCl3):  170.4, 162.1, 144.1, 141.8, 139.8, 134.1, 
130.4, 128.2, 125.6, 124.6, 122.4, 119.4, 115.5, 85.6, 
72.6, 66.4, 64.0, 51; MS: m/z (M++H) 575. Anal. 
Calcd for C30H24ClFN4O3S: C, 62.66; H, 4.21, N, 





thiazolidin-4-one, 10b: m.p. 216-218°C. Yield 72%. 




1H NMR (300 MHz, CDCl3): δ 8.09 (s, 1H, Ar-H), 
7.75 (s, 1H, CH=C), 7.62 (d, J=9.5 Hz, 2H, Ar-H), 
7.52 (d, J=9.4 HZ, 4H, Ar-H), 7.40 (d, J=8.6 HZ, 4H, 
Ar-H), 7.19 (d, J=8.1Hz, 2H, Ar-H), 5.84-5.75 (m, 2H 
,=CH), 4.94 (d, J=5.2Hz, 1H, CH-S), 4.52 (s, 2H, 
OCH2), 4.06-3.94 (m, 2H, 2×CH), 3.80 (t, 2H, 
OCH2): δ 
13C NMR (75 MHz,CDCl3):  170.5, 162.1, 
144.2, 139.2, 134.2, 130.4,129.2, 125.5, 124.1, 122.2, 
119.4, 85.4, 72.8, 65.4, 63.4, 51.2; MS: m/z (M++Na) 
632. Anal. Calcd for C30H23Cl2 FN4O3S: C, 59.12; H, 





thiazolidin-4-one, 10c: m.p.221-223°C. Yield 75%. 
1H NMR (300 MHz, CDCl3): δ 8.29 (d, J=8.7Hz, 2H, 
Ar-H), 8.09 (s, 1H, Ar-H), 7.69 (d, J=9.1Hz, 2H,Ar-
H), 7.65 (s, 1H, CH =C), 7.61 (d, J=9.4HZ, 2H, Ar-
H), 7.46 (d, J=8.5HZ, 2H, Ar-H), 7.18 (d, J=8.3Hz, 
2H, Ar-H), 6.84 (d, J=9.8Hz, 2H, Ar-H), 5.86-5.79 
(m, 2H, =CH), 4.96 (d, J=5.2Hz, CH-S), 4.55 (s, 2H, 
OCH2), 4.05-3.95 (m, 2H, 2×CH), 3.85 (d, J=6.9 Hz, 
2H, OCH2); 
13C NMR (75 MHz, CDCl3):  171.5, 
162.1, 144.0, 141.8, 134.2, 130.4, 128.5, 125.4, 119.5, 
115.4, 85.4, 72.4, 65.9, 63.6, 51.5; MS: m/z (M++H) 
620. Calcd for C30H23ClFN5O5S: C, 58.11; H, 3.74, N, 





4-one, 10d: m.p. 201-203°C. Yield 85%. 1H NMR 
(300 MHz, CDCl3): δ 8.08 (s, 1H, Ar-H), 7.69 (d, 
J=8.5Hz, 2H, Ar-H), 7.62 (s, 1H, CH =C), 7.56 (d, 
J=9.2 Hz, 2H, Ar-H), 7.49 (d, J=8.7 Hz, 2H, Ar-H), 
7.45-7.39 (m, 4H, Ar-H), 7.10 (d, J=9.1 Hz, 2H, Ar-
H), 5.76 (m, 2H, =CH), 4.93 (d, J=5.2 Hz, 1H, CHS), 
4.60 (s, 2H, OCH2), 4.05-3.96 (m, 2H, CH), 3.90 (t, 
2H, OCH2), 2.1 (s, 3H, CH3): δ 
13C NMR (75 MHz, 
CDCl3):  170.8, 162.9, 144.6, 137.2, 133.2, 130.6, 
130.4, 128.2, 125.9, 122.7, 119.2, 116.2, 115.4, 84.4, 
72.1, 65.3, 63.1, 52.5, 32.0, 17.5; MS: m/z (M++H) 
589. Anal. Calcd for C31H26ClFN4O3S: C, 63.21; H, 





one, 10e: m.p. 205-215°C, Yield 66%. 1H NMR (300 
MHz, CDCl3): δ 8.02 (s, 1H, Ar-H), 7.69 (s, 1H, CH 
=C), 7.65 (d, J=9.1Hz, 2H, Ar-H), 7.54 (d, J=9.2Hz, 
2H, Ar-H), 7.42 (d, J=8.7Hz, 2H, Ar-H), 7.35 (d, 
J=8.2 Hz, 2H, Ar-H), 7.18 (d, J=8.8 Hz, 2H, Ar-H), 
6.80 (d, J=9.4Hz, 2H, Ar-H), 5.70-5.69 (m, 2H, 
=CH), 4.94 (s, 1H, CHS), 4.55 (s, 2H, OCH2), 4.04-
3.98 (m, 2H, CH), 3.96 (t, 2H, OCH2), 2.32 (s, 3H, 
CH3); 
13C NMR (75 MHz, CDCl3):  170.1, 162.5, 
144.1, 139.5, 137.6, 135.2, 133.2, 130.4, 129.1, 127.5, 
124.1, 122.5, 119.5, 115.3, 85.1, 72.5, 66.1, 63.2, 
51.2, 21.6; MS: m/z (M++H) 589. Anal. Calcd for 
C31H26ClFN4O3S: C, 63.21; H, 4.45; N, 9.51. Found: 





din-4-one, 10f: m.p. 218-219°C. Yield 82%. 1H NMR 
(300 MHz, CDCl3): δ 9.42 (brs, 1H, Ph-OH), 8.08 (s, 
1H, Ar-H), 7.71 (d, J=9.7Hz, H, Ar-H), 7.65 (s, 1H, 
CH=C), 7.59 (d, J=9.3Hz, 2H, Ar-H), 7.44 (d, J=8.6Hz, 
2H, Ar-H), 7.15 (d, J=8.4 Hz, 2H, Ar-H), 6.80-6.78 (m, 
4H, Ar-H), 5.70-5.68 (m, 2H, =CH), 4.92 (d, J=5.2Hz, 
1H, CHS), 4.64 (s, 2H, OCH2), 4.10 (t, 2H, OCH2), 
4.01-3.98 (m, 2H, CH); 13C NMR (75 MHz,CDCl3):  
170.5, 162.1, 158.2, 143.8, 139.8, 134.5, 130.8, 128.6, 
125.6, 124.1, 122.4, 119.5, 115.7, 114.8, 106.5, 85.4, 
72.5, 66.4, 63.4, 51.5; MS: m/z (M++H) 591. Anal. 
Calcd for C30H24ClFN4O4S: C, 60.96; H, 4.09; N, 9.48. 





lidin-4-one, 10g: m.p.283-285°C. Yield 62%. 1H NMR 
(300 MHz, CDCl3): δ 9.42 (brs, 1H, Ph-OH), 8.05 (s, 
1H, Ar-H), 7.85 (d, J=9.3Hz, 2H, Ar-H), 7.65 (s, 1H, 
CH=C), 7.56 (d, J=9.2Hz, 2H, Ar-H), 7.46 (d, J=8.4 Hz, 
2H, Ar-H), 7.32 (d, J=8.6Hz, 2H, Ar-H), 7.19 (d, J=8.3 
Hz, 2H, ArH), 7.02 (d, J=8.8Hz, 2H, Ar-H), 5.89-5.80 
(m, 2H, =CH), 4.96 (d, J=5.4 Hz, 1H, CHS), 4.66 (s, 2H, 
OCH2), 4.09 (d, J=2H, OCH2), 4.04-3.98 (m, 2H, CH), 
13C NMR (75 MHz, CDCl3):  170.9, 162.5, 154.1, 
144.4, 139.8, 134.9, 134.8, 130.4, 128.8, 127.2, 125.6, 
123.2, 119.4, 116.4, 115.9, 85.4, 72.6, 66.5, 64.0, 51.6; 
MS: m/z (M++H) 591. Anal. Calcd for C30H24ClFN4O4S: 
C, 60.96; H, 4.09; N, 9.48. Found: C, 60.58; H, 3.95; N, 
9.23%. 
 
General procedure for the synthesis of Pyrazole 
phosphonates, 11a-g 
To a stirred mixture of 10a (1 mmol), and Bestmen 
Ohira Reagent (2.5mmol) in dry EtOH (10 mL) was 




added KOH (2.5mmol) at RT, after 2 min and 
irradiated in microwave bath reactor at 500 W for 4-7 
min at 50°C.The crude product thus obtained was 
purified by column chromatography on silica gel (60- 
120 mesh) with hexane-ethyl acetate as eluent. Under 
conventional method the reaction mixture in EtOH 







m.p.245-247°C. Yield 75%. 1H NMR (300 MHz, 
CDCl3): δ 13.06 (brs, 1H, -NH), 8.03 (s, 1H, Ar-H), 7.70 
(d, J=9.6Hz, 2H, Ar-H), 7.30 (d, J=9.2HZ, 2H, Ar-H), 
7.45 (d, J=8.9HZ, 2H, Ar-H), 7.19 (d, J=8.2Hz, 2H, Ar-
H), 6.95-6.70 (m, 5H, Ar-H), 5.80-5.74 (m, 2H, =CH), 
4.80 (d, J=5.2Hz, 1H, CH-S), 4.42 (s, 2H, OCH2), 4.09-
3.94 (m, 2H, 2×CH), 3.78 (s, 6H, OCH3), 3.69 (d, J=6. 
6Hz, 2H, OCH2), 3.52 (s, 1H, CH); 
13C NMR (75 MHz, 
CDCl3):  170.1, 160.1, 155.2, 144.1, 141.6, 136.2, 
134.1, 129.2, 127.5, 125.6, 122.1, 119.1, 115.8, 86.6, 
72.9, 63.8, 53.8, 44.5, 34.9; MS: m/z (M++H) 725. Anal. 
Calcd for C33H31ClFN6O6PS: C, 54.66; H, 4.31, N, 






ylphosphonate, 11b: m.p.206-208°C. Yield 82%. 
1H NMR (300 MHz, CDCl3): δ 13.11 (brs,1H,-NH), 
8.19 (s, 1H, Ar-H), 7.60 (d, J=9.5Hz, 2H, Ar-H), 7.54 
(d, J=9.4HZ, 4H, Ar-H), 7.30 (d, J=8.6HZ, 4H, Ar-H), 
7.22 (d, J=8.1Hz, 2H, Ar-H), 5.80-5.78 (m, 2H, = 
CH), 4.92 (d, J=5.2Hz, 1H, CH-S), 4.52 (s, 2H, 
OCH2), 4.06-3.94 (m, 2H, 2×CH), 3.80 (t, 2H, OCH2), 
3.68 (s, 6H, OCH3), 3.54 (s, 1H, CH); 
13C NMR (75 
MHz,CDCl3):  170.9, 162.1, 155.4, 144.2, 139.8, 
134.6, 129.5, 125.8, 124.1, 122.0, 119.2, 115.4, 86.1, 
72.5, 64.4, 53.5, 44.8, 34.9; MS: m/z (M++Na) 781. 
Anal. Calcd for C33H30Cl2 FN6O6PS: C, 52.18; H, 






ylphosphonate, 11c: m.p.231-233°C. Yield 82%. 
1H NMR (300 MHz, CDCl3): δ 13.06 (brs, 1H, -NH), 
8.23 (d, J=8.7Hz, 2H, Ar-H), 8.06 (s, 1H, Ar-H), 7.65 
(d, J=9.1Hz, 2H, Ar-H), 7.51 (d, J=9.4HZ, 2H, Ar-H), 
7.41 (d, J=8.5HZ, 2H, Ar-H), 7.10 (d, J=8.3Hz, 2H, Ar-
H), 6.64 (d, J=9.8Hz, 2H, Ar-H), 5.76-5.59 (m, 2H, 
=CH), 4.86 (d, J=5.2Hz, 1H, CH-S), 4.35 (s, 2H, 
OCH2), 4.01-3.93 (m, 2H, 2×CH), 3.72 (s, 6H, OCH3), 
3.65 (d, J=6.9 Hz, 2H, OCH2), 3.45 (s, 1H, CH); 
13C NMR (75 MHz, CDCl3):  171.1, 162.1, 150.0, 
147.8, 144.0, 136.8, 131.4, 128.8, 127.2, 122.0, 119.5, 
115.4, 86.4, 72.4, 65.9, 63.9, 53.5, 44.5, 34.8; MS: m/z 
(M++H) 780. Calcd for C33H30ClFN7O8PS: C, 51.47; H, 






11d: m.p.221-223°C. Yield 75%. 1H NMR (300 MHz, 
CDCl3): δ 13.10 (brs, 1H, -NH), 8.02 (s, 1H, Ar-H), 
7.59 (d, J=8.5Hz, 2H, Ar-H), 7.59 (d, J=9.2 Hz, 2H, 
Ar-H), 7.44 (d, J=8.7 Hz, 2H, Ar-H), 7.42-7.40 (m, 
4H, Ar-H), 7.12 (d, J=9.1Hz, 2H, Ar-H), 5.76 (m, 2H, 
=CH), 4.92 (d, J=5.2Hz, 1H, CHS), 4.62 (s, 2H,            
OCH2), 4.09-3.99 (m, 2H, CH), 3.74 (s, 6H, OCH3), 
3.62 (s, 1H, CH), 3.80 (t, 2H, OCH2), 2.12 (s, 3H, 
CH3): 
13C NMR (75 MHz, CDCl3):  170.4, 160.1, 
155.1, 144.4, 138.6, 136.2, 134.3, 130.7, 128.6, 127.2, 
122.0, 119.2, 116.9, 115.4, 86.1, 72.8, 63.8, 53.5, 
Table II — Synthesis of phosphonyl pyrazoles 11a-g 
Compd R Mol. Formula Reaction time Yield (%) 
A (h) B (min) A B 
11a C6H5 C33H31ClFN6O6PS 3.5 6 62 89 
11b 4-Cl-C6H4 C33H30Cl2FN6O6PS 2.5 4 60 85 
11c 4-NO2-C6H4 C33H30ClFN7O8PS 2.0 5 61 84 
11d 2-CH3-C6H4 C34H33ClFN6O6PS 3.0 6 65 86 
11e 4-CH3-C6H4 C34H33ClFN6O6PS 3.2 4 69 85 
11f 3-OH-C6H4 C35H31ClFN6O7PS 2.0 5 72 89 
11g 4-OH-C6H4 C35H35ClFN6O7PS 3.0 4 71 82 
A: Conventional method; B: Microwave Irradiation method 




44.9, 34.8, 17.9; MS: m/z (M++H) 739. Anal. Calcd 
for C34H33ClFN6O6S: C, 55.25; H, 4.50; N, 11.37. 






11e: m.p.209-211°C. Yield 76%. 1H NMR (300 MHz, 
CDCl3): δ 13.01 (brs, 1H, -NH), 8.07 (s, 1H, Ar-H), 
7.62 (d, J=9.1 Hz, 2H, Ar-H), 7.50 (d, J=9.2 Hz, 2H, 
Ar-H), 7.40 (d, J=8.7Hz, 2H, Ar-H), 7.32 (d, 
J=8.2Hz, 2H, Ar-H), 7.18 (d, J=8.8Hz, 2H, Ar-H), 
6.70 (d, J=9.4Hz, 2H, Ar-H), 5.60-5.59 (m, 2H, 
=CH), 4.90 (s, 1H, CHS), 4.45 (s, 2H, OCH2), 4.01-
3.99 (m, 2H, CH), 3.94 (t, 2H, OCH2), 3.75 (s, 6H, 
OCH3), 3.62 (s, 1H, CH), 2.30 (s, 3H, CH3); 
13C NMR 
(75MHz, CDCl3):  170.9, 160.1, 155.0, 144.1, 138.7, 
136.8, 133.4, 130.4, 129.1, 127.2, 122.0, 119.1, 115.3, 
86.1, 72.9, 68.1, 63.9, 53.5, 44.5, 34.8, 21.6; MS: m/z 
(M++H) 739. Anal. Calcd for C31H26ClFN4O3S: C, 







sphonate, 11f: m.p.228-229°C. Yield 88%. 1H NMR 
(300 MHz, CDCl3): δ 13.09 (brs, 1H, -NH), 9.40 (brs, 
1H, Ph-OH), 8.04 (s, 1H, Ar-H), 7.61 (d, J=9.7Hz, 
2H, Ar-H), 7.52 (d, J=9.3Hz, 2H, Ar-H), 7.42 (d, 
J=8.6Hz, 2H, Ar-H), 7.13 (d, J=8.4Hz, 2H, Ar-H), 
6.70-6.68 (m, 4H, Ar-H), 5.73-5.70(m, 2H, =CH), 
4.82 (d, J=5.2Hz, 1H, CHS), 4.54(s, 2H, OCH2), 4.14 
(t, 2H, OCH2), 4.0-3.97 (m, 2H, CH), 3.70 (s, 6H, 
OCH3), 3.57 (s, 1H, CH); 
13C NMR(75MHz,CDCl3): 
 170.2, 156.1, 155.2, 144.8, 136.8, 129.6, 128.2, 
127.5, 122.4, 119.4, 115.4, 106.5, 86.4, 72.5, 66.4, 
63.4, 53.5, 44.9, 34.3; MS: m/z (M++H) 741. Anal. 
Calcd for C33H31 ClFN6O7PS: C, 53.48; H, 4.22; N, 






ylphosphonate, 11g: m.p.293-295°C. Yield 69%. 
1H NMR (300 MHz, CDCl3): δ 12.85 (brs, 1H, -NH), 
9.32 (brs, 1H, Ph-OH), 8.02 (s, 1H, Ar-H), 7.65 (d, 
J=9.3Hz, 2H, Ar-H), 7.59 (d, J=9.2Hz, 2H, Ar-H), 
7.49 (d, J=8.4Hz, 2H, Ar-H), 7.30 (d, J=8.6Hz, 2H, 
Ar-H), 7.16 (d, J=8.3Hz, 2H, ArH), 7.0 (d, J= 8.8Hz, 
2H, Ar-H), 5.89-5.82 (m, 2H, =CH), 4.96 (d, J=5.4 
Hz, 1H, CHS), 4.56 (s, 2H, OCH2), 4.07 (d, J=2H, 
OCH2), 4.02-3.99 (m, 2H, CH), 3.82 (s, 6H, OCH3), 
3.62 (s, 1H, CH); 13C NMR (75 MHz, CDCl3):  
172.9, 160.5, 154.3, 144.6, 136.2, 134.9, 134.3, 130.4, 
129.8, 127.2, 125.6, 123.2, 119.8, 116.1, 86.4, 73.6, 
66.5, 64.0, 53.6, 44.8, 34.9; MS: m/z (M++Na) 763. 
Anal. Calcd for C33H31ClFN6O7PS: C, 53.48; H, 4.22; 
N, 11.34. Found: C, 53.18; H, 3.99; N, 11.13%. 
 
Conclusion 
In conclusion, a series of a new class of hybrid 
heterocyclics 11 a-g has been synthesized. The 
nematicidal activity of these compounds was 
evaluated against Dietylenchus myceliophagus and 
Caenorhabditis elegans. Among synthesized 
compounds 11b, 11c, 11f and 11g are the most 
effective against Dietylenchus myceliophagus and 
Caenorhabditis elegans the other test compounds 
showed moderate activity. 
 
Acknowledgements 
The authors are thankful to CSIR, New Delhi for 
the financial support (Project funding No: 02 
(247)15/EMR-II), Director CSIR-IICT, Hyderabad, 
India, for NMR and MS spectral analysis and 
Principal, Vaagdevi Degree and PG College 
Hanamkonda for his constant encouragement. 
 
References 
1 (a) Hani K D & Leigh D A, Chem Soc Rev, 39 (2010) 1240; 
(b) Kappa C O & Van der Eycken E, Chem Soc Rev,  
39 (2010) 1280; (c) El-Sagheer A H & Brown T, Chem Soc 
Rev, 39 (2010) 1388; (d) Qin A, Lam J W Y & Tang B Z, 
Chem Soc Rev, 39 (2010) 2522; (e) Meldal M & Tornoe C 
W, Chem Rev, 108 (2008) 2952; (f) Nandivada H, Jiang X & 
Lahann J, Adv Mater, 19 (2007) 2197; (g) Angell Y L & 
Burgess K, Chem Soc Rev, 36 (2007) 1674; (h) Fournier D, 
Hoogenboom R & Chubert U S S, Chem Soc Rev, 36 (2007) 
1369; (i) Moses J E & Moorhouse A D, Chem Soc Rev, 36 
(2007) 1249; (j) Lutz J F, Angew Chem Int Ed, 46 (2007) 
1018; (k) A Dondoni, Chem Asian J, 2 (2007) 700; (l) Kolb 
H C & Sharpless K B, Drug Discovery Today, 8 (2003) 
1128. 
2 (a) Zhou Ch & Wang Y, Curr Med Chem, 19 (2012) 239; 
(b) Brick A, Muldoon J, Lin Y C, Elder J H, Goodsell D S, 
Olson A J, Fokin V V, Sharpless K B & Wong C H, 
ChemBioChem, 4 (2003) 1246; (c) Soltis M J, Yeh H J, Cole 
K A, Whittaker N, Wersto R P & Kohn E C, Drug Metab 
Dispos, 24 (1996) 799. 
3 (a) Fan W-Q & Katritzky A R, ‘1,2,3-Triazoles’, in 
Comprehensive Heterocyclic Chemistry II, edited by A R 
Katritzky, C W Rees and V Scriven (Elsevier, Oxford) 1 




(1996) 905; (b) Whiting M, Muldoon J, Lin Y C, Silverman 
S M, Lindstrom W, Olson A J, Kolb H C, Finn M G, 
Sharpless K B, Elder J H & Fokin V V, Angew Chem Int Ed, 
45 (2006) 1435; (c) Bourne Y, Kolb H C, Radić Z, Sharpless 
K B, Taylor P & Marchot P, Proc Natl Acad Sci (USA), 101 
(2004) 1449; (d) Lewis W G, Green G, Grynszpan F Z, 
Carlier P R, Taylor P, Finn M G & Sharpless K B, Angew 
Chem Int Ed, 41 (2002) 1053. 
4 1,3-Dipolar Cycloaddition Chemistry, edited by Huisgen Y 
and Padwa A (Wiley, New York), 1 (1984) 1. 
5 (a) Al Maoudi N A & Al Soud A Y, Tetrahedron Lett, 43 
(2002) 4021; (b) Kuijpers M H B, Groothuys S, Keereweer R 
A B, Quaedflieg P J L M, Blaauw R H, van Delft F L & 
Rutjes F P J T, Org Lett, 6 (2004) 3123; (c) Ch Srinivas F P J 
T, Fang X & Wang Q, Tetrahedron Lett, 46 (2005) 2331; (d) 
Hotha S, Anegundi R I & Natu A A, Tetrahedron Lett, 46 
(2005) 4585; (e) Hotha S & Kashyap S, J Org Chem, 71 
(2006) 364. 
6 Andrew S, Susan M, Michael F, Mathew W, Penny L, Paul 
L, Anne G, Chris B, John M, Donald T, Dennis S & Tesfaye 
B, Bioorg Med Chem Lett, 18 (2008) 5263. 
7 Onca S, Punar M & Eracosy H, Chemotherapy, 50 (2004) 98. 
8 Dave C V & Shukla M C, Indian J Chem, 39B (2000) 
210. 
9 Ghazzi M N, Perez E, Antonucci T K, Driscoll H, Hunang S 
M & Faja B W, Diabetes, 46 (1997) 433. 
10 Scmidt U, Utz R, Liberknecht A, Griesser H, Potzolli B, 
Bahr J, Wagner K & Fischer P, Synthesis, 233 (1978). 
11 Diurno M V, Mazzoni O, Lzzo A A & Bolognese A,  
II Farmaco, 52 (1992) 237. 
12 Ergene N & Gapan G, II Farmaco, 49 (1994) 237. 
13 Viswajanani J S, Ajay S, Smita S, Seema K, Manisha P, 
Pragya B, Tarun M, Ashok R, Jagmohan K & Anitha M, 
Arkivoc, 46 (2005). 
14 Ueno H, Oe T, Snehiro I & Nakamura S, US Patent, 
5594116 (1997). 
15 Previtera T, Vigortia M G, Bisila M, Orsini F, Benetolla F & 
Bombieri G, Eur J Med Chem, 29 (1994) 317. 
16 Ebied M Y, Fathallah O A, El Zaheer M I, Kamel M M, 
Abdon W A & Anwer M M, Bull Fac Pharm, 34 (1996) 125. 
17 Rawal R K, Prabhakar Y S, Katti S B & Declercq E, Bio Org 
Med Chem, 13 (2005) 6771. 
18 Kato T, Ozaki T & Tamura K, J Med Chem, 42 (1999) 3134. 
19 Tanabe Y, Suzukamo G, Komuro Y, Imanishi N, Morooka S, 
Enomoto M, Kojima M, Sanemistu Y & Mizutani M, 
Tetrahedron Lett, 32 (1991) 379. 
20 Kato T, Ozaki T & Ohi N, Teraherdron Assymetry, 10 
(1999) 3963. 
21 Adachi Y, Suzuki Y, Homma N, Fukazawa M, Tamura K, 
Nishie I & Kurumaro O, Eur J Pharmacol, 367 (1999) 267. 
22 Ottana R, Mazzon E, Dugo L, Monforte F, Macari F, 
Sautebin L, De Luca D, Vigorita M G, Alcaro S & Orusto F, 
Eur J Pharmacol, 448 (2002) 71. 
23 Tanabe Y, Yamamoto H, Murakami M, Yanagi K, Kubota Y, 
Okumara H, Sanemistu Y & Suzukamo G, J Chem Soc 
Perkin Trans, 17 (1995) 935. 
24 Kato Y F, Kita Y, Nisho M, Hirasawa Y, Ito K, Yamanaka T, 
Motoyana Y & Seki J, Eur J Pharmacol, 384 (1999) 197. 
25 Voss M E, Carter P H, Tebben A J, Scherie P A, Brown G D, 
Thampson L A, Xu M, Lo Y C & Yang-Liu R R Q, Bio Org 
Med Chem Lett, 13 (2003) 6771. 
26 Field S C, Tetrahedron, 55 (1999) 12237. 
27 (a) Moonen K, Laureyn I & Stevens C V, Chem Rev, 104 
(2004) 6177; (b) Piperno A, Chiachio D, Lannazo D & 
Romco R, Curr Med Chem, 13 (2006) 3675. 
28 (a) Qu G R, Xia R, Yang X N, Li J G, Wang D C & Guo H 
M, J Org Chem, 73 (2008) 2416; (b) Alen J, Dobrazanaska 
L, Dc Borggraeve W M & Compernolle F J, J Org Chem, 72 
(2007) 1055; (c) Moriguchi T, Yanagi Y, Kunimori M, Weda 
T & Sekni M J, J Org Chem, 65 (2000) 8229. 
29 Lamberth C, Heterocyclics, 71 (2007) 1467. 
30 McDonald E, Jones K, Brough P A, Drysdale M J & 
Workman P, Curr Top Med Chem, 6 (2006) 1193. 
31 Halcrow M A, Dalton Trans, 2059 (2009). 
32 Jayasinghe U L B, Kumarihamy B M M, Bandara A G D, 
Vasquez E A & Karus W, Nat Prod Res, 17 (2003) 259. 
33 Xaki M H, Moran D & Harries D, Am J Public Health, 72 
(1982) 1391. 
34 Noling J W & Becker J O, J Nematol, 26 (1994) 573. 
35 Kagan J, Kagan P A & Bushe H E, J Chem Ecol, 10 (1984) 1115. 
36 Yuji O, Sengual N, Eli P, Uzi R, Zohara Y & Yitzhak S, 
Phytopathology, 90 (2000) 710. 
37 Srinivas A, Sunitha M, Karthik P, Nikitha G, Raju K, 
Ravinder B, Anusha S, Rajasri T, Swapna D, Swaroopa D, 
Srinivas K & Vasumathi Reddy K, J Heterocycl Chem, 54 
(2017) 3250. 
38 Srinivas A, Santhosh M, Sunitha M, Karthik P, Srinivas K & 
Vasumathi Reddy K, Acta Chim Slov, 63 (2016) 827. 
39 Srinivas A, Acta Chim Slov, 63 (2016) 344. 
40 Srinivas A & Sunitha M, Indian J Chem, 55B (2016) 102. 
41 Srinivas A & Sunitha M, Indian J Chem, 55B (2016) 231. 
42 Reddy C S, Srinivas A, Sunitha M & Nagaraj A, J 
Heterocycl Chem, 47 (2010) 1303. 
43 Srinivas A, Reddy C S & Nagaraj A, Chem Pharm Bull, 57 
(2009) 685. 
44 Reddy C S, Srinivas A & Nagaraj A, J Heterocycl Chem, 46 
(2009) 497. 
45 Reddy C S, Srinivas A & Nagaraj A, J Heterocycl Chem, 45 
(2008) 1121. 
46 McBeth C W & Bergerson G B, Phytopathology, 43 (1953) 26 
 
